论文部分内容阅读
由于PET在心肌灌注显像方面具有高分辨率、高灵敏度、低组织衰减和心肌血流定量等优势而使得PET心肌灌注显像剂的研究日益受到关注。本文介绍了目前已经应用于临床的PET心肌灌注显像剂的情况,分别综述了18F标记和其他正电子核素标记的PET心肌灌注显像剂的研究进展,重点讨论了几种亲脂性阳离子类和线粒体复合物Ⅰ(MC-Ⅰ)抑制剂类18F标记心肌灌注显像剂,特别是近年取得突破性进展的MC-Ⅰ抑制剂类心肌灌注显像剂(如BMS-747158-02和[18F]FP1OP),介绍了各类PET心肌灌注显像剂的生物性能、心肌摄取机制,对其优缺点进行比较,并对PET心肌灌注显像剂的应用前景进行了展望。
Due to the advantages of high resolution, high sensitivity, low tissue attenuation and quantification of myocardial blood flow in PET myocardial perfusion imaging, the research of PET myocardial perfusion imaging has attracted more and more attention. This article introduces the clinical application of PET myocardial perfusion imaging agent, reviewed the research progress of 18F labeling and other positron-tagged PET myocardial perfusion imaging agents, focusing on several lipophilic cationic species And 18F-labeled myocardial perfusion imaging agents of mitochondrial complex I (MC-I) inhibitors, especially MC-I inhibitor myocardial perfusion imaging agents (such as BMS-747158-02 and [18F ] FP1OP), describes the biological properties and myocardial uptake mechanisms of various types of PET myocardial perfusion imaging agents, and compares their advantages and disadvantages. The prospect of PET myocardial perfusion imaging agents is also prospected.